Boston Scientific Corporation (BSX) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Boston Scientific Corporation (BSX) right now is Farapulse and the Pulsed Field Ablation Wave: The Farapulse pulsed field ablation (PFA) system is the single most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. Revenue (TTM) is ~$20.6 billion. If that keeps playing out, the setup is favourable; the risk to it is the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. No one can predict where BSX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Boston Scientific Corporation (BSX) higher?
1. Farapulse and the Pulsed Field Ablation Wave
The Farapulse pulsed field ablation (PFA) system is the single most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. PFA is reshaping atrial fibrillation treatment by ablating tissue with less collateral damage than older thermal methods, and Boston Scientific was an early leader in the category. The durability of this lead against Medtronic and Johnson and Johnson PFA offerings is the key long-term question.
2. Watchman Franchise Expansion
The Watchman left-atrial-appendage closure device generated roughly $535 million in fourth-quarter 2025 sales, up about 29% year over year, driven by growing adoption of concomitant procedures that combine Watchman with ablation in a single visit. The franchise addresses stroke-risk reduction in atrial fibrillation patients who cannot tolerate long-term blood thinners. Continued clinical evidence and label expansion underpin the growth thesis here.
3. Cardiovascular Leadership and Structural Heart
Beyond electrophysiology, the broader Cardiovascular segment delivered roughly 21% organic growth for full-year 2025, spanning interventional cardiology, peripheral interventions, and structural heart. This breadth gives Boston Scientific multiple procedure-volume tailwinds tied to an aging global population and the ongoing shift toward minimally invasive treatment. Recent and pending product approvals broaden the addressable patient base.
4. MedSurg Diversification
The MedSurg segment, covering endoscopy, urology, and neuromodulation, provides steadier mid-single-digit growth that diversifies the company away from pure cardiovascular exposure. While it grows more slowly than Cardiovascular, it contributes meaningful recurring revenue and cross-selling into the same hospital customer base. Management continues to invest in and occasionally acquire adjacent technologies to strengthen these franchises.
What could weigh on BSX?
The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus.
Where BSX trades today
A forecast starts from where the stock actually is. These are BSX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for BSX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a BSX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BSX guide and whether BSX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BSX outlook
The bottom line: what is driving Boston Scientific Corporation (BSX) is Farapulse and the Pulsed Field Ablation Wave, with revenue (ttm) at ~$20.6 billion. If that keeps playing out the setup is favourable; the risk is the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. No one can predict the price, so treat any BSX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around BSX with Walnut
Use Boston Scientific Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Boston Scientific Corporation (BSX)?
+
No one can reliably predict where BSX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Boston Scientific Corporation higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BSX higher?
+
The main growth drivers are Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion; Cardiovascular Leadership and Structural Heart. Whether they play out is the real question, not a guaranteed path.
What are the risks to BSX?
+
The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus.
Will BSX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Boston Scientific Corporation's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BSX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BSX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Why did BSX stock fall despite strong growth?
+
Boston Scientific shares fell sharply even though full-year 2025 growth was strong because the stock had carried a high premium valuation and management guided 2026 organic growth down to roughly 6.5% to 8%, citing unanticipated headwinds in electrophysiology, Watchman, and urology. When a premium-multiple growth stock signals deceleration, share-price reactions can be outsized even when absolute growth remains healthy.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.